美國Wistar研究所的研究人員最近發(fā)現(xiàn)血液中存在的免疫系統(tǒng)標(biāo)記物,，或許利用該標(biāo)記物能夠預(yù)測早期肺部腫瘤患者發(fā)生肺癌的可能性,。這項研究發(fā)表在12月1日Cancer Research雜志上?；蛟S有助于科學(xué)家開發(fā)一種簡單的血液檢測方法,，用來診斷早期肺癌。
在這項研究中,，賓夕法尼亞大學(xué)醫(yī)學(xué)院和紐約大學(xué)醫(yī)學(xué)院提供了2002年至2007年間肺癌患者的外周血(peripheral blood)樣本,。Wistar研究所在對這些樣本分析基因表達(dá)模式。研究人員發(fā)現(xiàn),，利用一個29-“標(biāo)簽基因”(a 29-gene "signature")能夠?qū)?37位非小細(xì)胞肺癌(NSCLC)患者和91位一般性肺病患者區(qū)別開,，且正確率為86%,。
研究人員在18名非小細(xì)胞肺癌在接受手術(shù)前收集了他們的外周血樣本,，并在這些患者手術(shù)清除腫瘤后2～5個月后再次收集他們的外周血，對這兩個不同階段的血液樣本研究發(fā)現(xiàn),，其中有13名患者在接受手術(shù)前還存在著的腫瘤基因標(biāo)簽,，手術(shù)后這些標(biāo)簽明顯減少甚至完全消失,。這項發(fā)現(xiàn)證實，機(jī)體發(fā)生腫瘤的信號能夠傳遞給外周免疫系統(tǒng),，而這種信號能夠通過對外周血的基因表達(dá)模式檢測到,。（生物谷Bioon.com）
生物谷推薦原始出處：
Cancer Research, 10.1158/0008-5472.CAN-09-1378
Gene Expression Profiles in Peripheral Blood Mononuclear Cells Can Distinguish Patients with Non–Small Cell Lung Cancer from Patients with Nonmalignant Lung Disease
Michael K. Showe1, Anil Vachani2, Andrew V. Kossenkov1, Malik Yousef1, Calen Nichols1, Elena V. Nikonova1, Celia Chang1, John Kucharczuk2, Bao Tran2, Elliot Wakeam2, Ting An Yie3, David Speicher1, William N. Rom3, Steven Albelda2 and Louise C. Showe1
1 The Wistar Institute; 2 Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; and 3 Division of Pulmonary and Critical Care Medicine, New York University School of Medicine, New York, New York
Early diagnosis of lung cancer followed by surgery presently is the most effective treatment for non–small cell lung cancer (NSCLC). An accurate, minimally invasive test that could detect early disease would permit timely intervention and potentially reduce mortality. Recent studies have shown that the peripheral blood can carry information related to the presence of disease, including prognostic information and information on therapeutic response. We have analyzed gene expression in peripheral blood mononuclear cell samples including 137 patients with NSCLC tumors and 91 patient controls with nonmalignant lung conditions, including histologically diagnosed benign nodules. Subjects were primarily smokers and former smokers. We have identified a 29-gene signature that separates these two patient classes with 86% accuracy (91% sensitivity, 80% specificity). Accuracy in an independent validation set, including samples from a new location, was 78% (sensitivity of 76% and specificity of 82%). An analysis of this NSCLC gene signature in 18 NSCLCs taken presurgery, with matched samples from 2 to 5 months postsurgery, showed that in 78% of cases, the signature was reduced postsurgery and disappeared entirely in 33%. Our results show the feasibility of using peripheral blood gene expression signatures to identify early-stage NSCLC in at-risk populations.
